Loading
Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer.
Jean-Pascal Machiels heads medical oncology at Cliniques universitaires Saint-Luc in Brussels and chairs the EORTC head and neck cancer group. He was first author of the 2024 Lancet Oncology report of KEYNOTE-412, the phase 3 trial of pembrolizumab with and after cisplatin-based chemoradiotherapy in locally advanced head and neck squamous-cell carcinoma, which did not reach statistical significance for event-free survival, and of the European guidelines for the disease.
| Title | Journal | Year |
|---|---|---|
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 1354 citations on Europe PMC. | The Lancet | 2019 |
| Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 672 citations on Europe PMC. | Annals of Oncology | 2020 |
| Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 332 citations on Europe PMC. | Annals of Oncology | 2021 |
One of the most cited papers Europe PMC returns for Jean-Pascal Machiels at King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Jean-Pascal Machiels at King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Jean-Pascal Machiels at King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy, trialist.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy, trialist.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, trialist.
Shares the tags immunotherapy, trialist.
Shares the tags immunotherapy, trialist.